SCHEMBL30936705

SCHEMBL30936705

CNc1c(C)cccc1NS(=O)(=O)c1ccc(S(=O)(=O)N(C)C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.50
MCOLN2 Q8IZK6 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
ALDH1A1 P00352 6/20 0.48
KMT2A Q03164 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
FFAR4 Q5NUL3 1/20 0.48
KEAP1 Q14145 2/20 0.46
MAPT P10636 4/20 0.43
LMNA P02545 3/20 0.43
USP2 O75604 1/20 0.43
POLB P06746 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NOD2 Q9HC29 1/20 0.43
KDM4E B2RXH2 1/20 0.42
LIMK2 P53671 1/20 0.42
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30936607 0.85 MCOLN2 (0.60) TSHRMCOLN2ALDH1A1KMT2ASMN1; SMN2
SCHEMBL30936685 0.85 MCOLN2 (0.48) TSHRMCOLN2L3MBTL1ALDH1A1KMT2A
SCHEMBL23057255 0.84 MAPT (0.58) TSHRMCOLN2L3MBTL1ALDH1A1KMT2A
SCHEMBL30936619 0.81 MCOLN2 (0.51) TSHRMCOLN2L3MBTL1ALDH1A1KMT2A
SCHEMBL31720617 0.74 MCOLN2 (0.54) MCOLN2L3MBTL1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL23057210 0.74 KEAP1 (0.51) TSHRMCOLN2L3MBTL1ALDH1A1KMT2A
SCHEMBL29979016 0.74 MCOLN2 (0.50) TSHRMCOLN2L3MBTL1ALDH1A1KMT2A
SCHEMBL23043640 0.74 MCOLN2 (0.50) TSHRMCOLN2L3MBTL1ALDH1A1KMT2A
SCHEMBL29978580 0.74 KEAP1 (0.51) TSHRMCOLN2L3MBTL1ALDH1A1KMT2A
SCHEMBL30936634 0.72 L3MBTL1 (0.46) TSHRMCOLN2L3MBTL1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340510-A1 Substituted Phenylbenzenesulfonamide Derivatives and Uses Thereof NINE SQUARE THERAPEUTICS CORPORATION (US) 2025-11-06 US disclosed
EP-4608389-A2 SUBSTITUTED PHENYLBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF Nine Square Therapeutics Corporation (US) 2025-09-03 EP disclosed
WO-2024092235-A2 SUBSTITUTED PHENYLBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF NINE SQUARE THERAPEUTICS CORPORATION (US) 2024-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340510-A1 Substituted Phenylbenzenesulfonamide Derivatives and Uses Thereof TRPM2, TRPM6, TRPM5 TSHR 4552/4885MCOLN2 19/4885L3MBTL1 2204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.